Screening tool has a much larger market appeal, cheaper and...

Screening tool has a much larger market appeal, cheaper and faster to launch and we have little competion in the space (doesn't need a whole lot of time and money to disrupt). Something like our tech would be:

1. Very threatening to large diagnostic companies and thus be a dangerous field to try and disupt

2. Requiring a huge campaign to get doctors on board to refer us over a traditional test

These hurdles are much to big for a company our size and imo would have been a 'let's put all our eggs in FDA basket' situation which could have been another disaster. It's clear from this direction of the company that they have learnt from mistakes and taken the safer option. If we build up our rep in this space then there is no reason why a diagnostic tool couldn't be launched. However, as we are complimentary to the huge OSA companies like Resmed and Philips then a referral type partnership is also a no brainer and possibly launching a diagnostic tool alongside them in the future (similar to what we are working on with RB for the respiratory app atm) .

Watch this space